AbbVie Says Phase 3 Trial of Lutikizumab in Hidradenitis Suppurativa Meets Endpoints
MT newswire2026/10/22 13:44Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
09:44 AM EDT, 10/22/2026 (MT Newswires) -- AbbVie (ABBV) said Thursday that topline results from a phase 3 study evaluating lutikizumab in adults and adolescents with moderate to severe hidradenitis suppurativa met its primary and secondary endpoints. The company said patients treated with lutikizumab had significantly higher response rates for the primary endpoint of Hidradenitis Suppurativa Clinical Response 75, or HiSCR75, at week 16 compared with placebo. HiSCR75 is defined as at least a 75% reduction from baseline in the total abscess and inflammatory nodule count, with no increase in abscess count and no increase in draining fistula count relative to baseline, AbbVie said. The company added that lutikizumab also delivered statistically significant improvements for key secondary endpoints, including rapid reductions in hidradenitis suppurativa-related pain and significantly fewer flares, compared with placebo. Shares of AbbVie were down 1.8% in early trading Thursday. Price: 279.54, Change: -5.18, Percent Change: -1.82
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like

Take-Two (TTWO.US) subsidiary Rockstar ramps up GTA6 promotion on TikTok for Thursday's global launch: Not yet approved in China, overseas preorders approach 16 million
Rockstar Games, a wholly owned video game subsidiary of Take-Two, is promoting its major title "Grand Theft Auto VI" (GTA6) to hundreds of thousands of Chinese social media followers. The game is set for global release on Thursday; however, it has not yet received approval for sale in mainland China.
智通财经•2026/11/18 09:02

Masayoshi Son admits not investing in Anthropic was a mistake
Chaincatcher•2026/11/18 08:17
Crypto prices
MoreBitcoin
BTC
$64,364.94
+0.29%
Ethereum
ETH
$1,804.81
+0.58%
Tether USDt
USDT
$0.9988
-0.01%
BNB
BNB
$590.82
+0.28%
USDC
USDC
$0.9998
+0.00%
XRP
XRP
$0.9994
+4.60%
Solana
SOL
$74.81
+3.47%
TRON
TRX
$0.3084
+1.01%
Hyperliquid
HYPE
$68.65
-0.43%
Zcash
ZEC
$939.74
+1.38%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now